Vedolizumab Therapy for Crohn's Disease
Evaluation Timeline for Vedolizumab Response
- The Canadian Association of Gastroenterology recommends evaluating patients with Crohn's disease for symptomatic response to vedolizumab therapy between 10 and 14 weeks to determine the need to modify therapy 1, 2, 3
- Patients with Crohn's disease who receive vedolizumab should be assessed for treatment response after completing the recommended evaluation period, as the full induction effect may not yet be evident within the first few weeks of treatment 1, 2
Continuation Criteria and Clinical Rationale
- The European Crohn's and Colitis Organisation (ECCO) strongly recommends vedolizumab for maintaining clinical remission in patients who achieved remission with vedolizumab 5
Monitoring and Next Steps
- The physician's plan to check for Clostridium difficile infection and evaluate for small bowel stricture is appropriate, as these factors could contribute to persistent symptoms despite effective therapy 6, 7
Conclusion on Medical Necessity
- Continued Entyvio infusion every 8 weeks is medically necessary for patients with Crohn's disease who are still within the recommended evaluation period, according to the Canadian Association of Gastroenterology 1, 2
- Patients with Crohn's disease should be reassessed after completing the recommended evaluation period (10-14 weeks) to determine if treatment modification is needed 2, 4